New National Security Checks Could Hinder Investment, Warns UK Biotech Sector
Synthetic Biology In Spotlight
Life science SMEs and their investors need to comply with new UK government checks on their dealmaking.
You may also be interested in...
Post-Brexit Britain offers a fertile R&D ecosystem, but it needs to improve uptake in novel medicines there and strike a lasting deal with the EU over batch testing, Novo Nordisk’s UK general manager Pinder Sahota tells Scrip.
Key investors have pledged more patience in CEO Walmsley’s turnaround but they will be expecting a convincing vision of the future, more dynamic, GSK.
Aiming to mimic public-private COVID-19 vaccine success, the US NIH will fund pandemic drug research, including taking candidates up to Phase II.